Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours - Leonowens, Cathrine; Pendry, Carolyn; Bauman, John; Young, Graeme C.; Ho, May; Henriquez, Frank; Fang, Lei; Morrison, Royce A.; Orford, Keith; Ouellet, Daniele (British journal of clinical pharmacology, 2014)
Keywords: Administration, Intravenous; Administration, Oral; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; bioavailability; Biological Availability; Female; Half-Life; Humans; intravenous; Male; MAP Kinase Kinase 1 - antagonists & inhibitors; MAP Kinase Kinase 2 - antagonists & inhibitors; microtracer; Neoplasms - drug therapy; pharmacokinetic; Pharmacokinetics; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - therapeutic use; Pyridones - administration & dosage; Pyridones - pharmacokinetics; Pyridones - therapeutic use; Pyrimidinones - administration & dosage; Pyrimidinones - pharmacokinetics; Pyrimidinones - therapeutic use; Tissue Distribution; trametinib; trametinib; intravenous; pharmacokinetic; bioavailability; microtracer